Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRUM-007: HLX10 (Serplulimab) in First-line Advanced ESCC
NCT03958890Phase 3Unknown
- Sponsor
- Henlius
- Start
- Jun 2019
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henlius. Status: unknown.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03958890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958890.